Inflation Reduction Act and Its Impact on Pharmaceutical Pricing and Investment Decisions
November 23rd 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.